This study is testing Qudexy XR, an extended-release capsule, to see if it can help prevent migraine headaches in children aged 6 to 11 years old. Some children will receive Qudexy XR, while others will receive a placebo (an inactive capsule that looks the same). The main goal is to see if Qudexy XR reduces the number of headache days over an 8-week period, compared to the start of the study. To join, children need to be between 6 and 11 years old, weigh between 17 and 50 kg, and have had migraines for at least 6 months. The study plans to enroll 132 children, but its current status is unclear.

Study design

This is an interventional study, meaning participants will receive either Qudexy XR or a placebo. It aims to enroll 132 children.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 16 weeks, suggesting follow-up for at least that duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.